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Background: Over the past 20 years evidence has accumulated confirming the immunomodulatory role of the
appendix in ulcerative colitis (UC). This led to the idea that appendectomy might alter the clinical course of
established UC. The objective of this body of research is to evaluate the short-term and medium-term efficacy of
appendectomy to maintain remission in patients with UC, and to establish the acceptability and cost-effectiveness
of the intervention compared to standard treatment.
Methods/Design: These paired phase III multicenter prospective randomised studies will include patients over
18 years of age with an established diagnosis of ulcerative colitis and a disease relapse within 12 months prior to
randomisation. Patients need to have been medically treated until complete clinical (Mayo score <3) and endoscopic
(Mayo score 0 or 1) remission. Patients will then be randomised 1:1 to a control group (maintenance 5-ASA treatment,
no appendectomy) or elective laparoscopic appendectomy plus maintenance treatment. The primary outcome
measure is the one year cumulative UC relapse rate - defined both clinically and endoscopically as a total Mayo-score
≥5 with endoscopic subscore of 2 or 3. Secondary outcomes that will be assessed include the number of relapses per
patient at 12 months, the time to first relapse, health related quality of life and treatment costs, and number of
colectomies in each arm.
Discussion: The ACCURE and ACCURE-UK trials will provide evidence on the role and acceptability of appendectomy
in the treatment of ulcerative colitis and the effects of appendectomy on the disease course.
Trial registration: NTR2883; ISRCTN56523019
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Ulcerative Colitis (UC) is an inflammatory bowel disease
that diffusely affects the mucosa of the colon at variable
distance from the anal verge. The aetiology of UC is not
fully understood, although it is considered to be multi-
factorial with genetic and environmental factors leading
to an inappropriate immunologic response [1,2]. Cytokine
imbalance and the production of inflammatory mediators
by activated CD4+ T cells are thought to play an import-
ant role in the pathogenesis of UC. T-helper type 2 cells
and their cytokines are suggested to enhance the develop-
ment of UC [1].
The primary treatment of UC is medical, first with
5-aminosalicyclic acids (5-ASA) and/or corticosteroids.
More refractory patients need immunosuppression with
thiopurines, calcineurin inhibitors or TNF alpha blockers.
In disease refractory to medical treatment, a (staged)
proctocolectomy with ileo-anal pouch anastomosis is usu-
ally performed. Approximately 30% of UC patients even-
tually require surgery [3-6].
A significant proportion of UC patients will remain on
long term medication to maintain remission and prevent
relapse, which carries significant morbidity and impacts
considerably on quality of life and health resource util-
isation. The peak age of onset of UC is 20–35 years old,
which means that this condition has a significant impact
on working life and potentially procreation and childcare.
Multicentre pooled data suggest that after a flare-up of
UC, the annual relapse rate without medication ranges
between 40-76%. Even on long-term maintenance ther-
apy up to 40% of patients will still experience at least
one relapse within the year, which will require treatment
again often including corticosteroids with its incumbent
risks and toxicity [7].
Over the past 20 years a substantial body of evidence
has accumulated supporting a role for the appendix in
the development and course of UC. There is a strong
inverse relationship between prior appendectomy (most
frequently for appendicitis) and the development of UC,
documented through multiple epidemiological and case–
control studies from diverse populations [8-10]. Several
studies have also investigated the effect of appendectomy
on established UC. In a systematic review we have shown
that appendectomy might influence the disease course in
UC patients, with possible reductions in relapse rates,
need for immunosuppression and colectomy rates in UC
patients who had an appendectomy, although the hetero-
geneity of the available studies and subjective nature of
the endpoints made direct comparison difficult [11]. Fur-
thermore, it was shown in a T-cell receptor knockout
mouse model for colitis that an early appendectomy sup-
pressed inflammation [12]. Another study showed that
the proportion of CD4 + CD69+ T cells was significantly
increased in the appendix of UC patients, compared tothe appendix of controls [13]. In addition, endoscopists
have reported on ‘skip lesions’ around the caecal orifice
of the appendix in UC patients (referred to as the caecal
patch or PARP: peri-appendicular red patch), which is
seen even in distal colitis without caecal involvement in
48-86% of patients [10,13-18]. Consequently, the appen-
dix is suggested to be a priming site in the development
of UC.
This research body will prospectively evaluate the role
of the appendix in UC and the potential effect of ap-
pendectomy on the disease course.
Methods/Design
Study objective
The objective of these paired studies is to evaluate the
short-term and medium-term efficacy of appendectomy
to maintain remission in patients with an established
diagnosis of mild to moderate ulcerative colitis, to assess
the safety and morbidity profile of the intervention, and
to explore its acceptability, both to patients with ulcera-
tive colitis and the clinicians responsible for their care.
Study design
1) ACCURE Trial (Netherlands) - A multicenter
randomised clinical trial aiming at patients with an
established diagnosis of ulcerative colitis and a
disease relapse within 12 months prior to
randomisation, medically treated (for treatment
with immunomodulators and biologicals a wash
out period of 3 months before inclusion is required)
until full clinical and endoscopic remission has been
achieved as defined by the Mayo score.
2) ACCURE-UK Trial (UK) - This parallel study is a
randomised external pilot and feasibility study utilising
a matched overall study design, including the same
patient population, intervention, and outcome
measures.
Primary and secondary endpoints
The primary endpoint of both trials is the one year
cumulative UC relapse rate, defined both clinically and
endoscopically as Mayo-score ≥5 with endoscopy sub
score of 2 or 3.
Secondary endpoints are the number of relapses per
patient in the first year after randomisation, the time to
first relapse, disease activity, health related quality of life
and treatment costs, and finally the number of colecto-
mies. During longer term follow up beyond one year,
disease activity including number of relapses and num-
ber of colectomies will be measured.
In addition, ACCURE-UK also aims to explore if the
appendectomy intervention is an acceptable treatment
option to UC patients and clinicians, establish throughput
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bidity profile of the intervention in this novel setting.
Study population
Patients are eligible for both trials when they meet the
following inclusion criteria:
(1)Aged ≥ 18 years.
(2)Histologically confirmed diagnosis of UC.
(3)Disease relapse within 12 months prior to
randomisation.
(4)In remission on 5-ASA or after a wash out period
of at least 3 months after treatment with
immunomodulators and biologicals (if given).
(5)Clinical (Mayo score <3) and endoscopic (Mayo
score 0 or 1) remission at time of randomisation.
(6)Negative stool culture and C. Difficile toxin.
Patients will be excluded when:
(1)A prior appendectomy has been performed.
(2)Previous major abdominal surgery that may prevent
safe and straightforward appendectomy has been
performed.
(3)Any suspicion of Crohn’s disease is present.
(4)A toxic megacolon or severe ongoing colitis is
present at time of randomisation.
(5)Diagnosed with active extra-intestinal infections, liver
or kidney failure, major lung or heart co-morbidity.Figure 1 Study profile.Participating centres
Nine teaching hospitals in the Netherlands will partici-
pate in the ACCURE trial and six hospitals in the
United Kingdom in the ACCURE-UK trial, including 4
academic centres.
Ethics
These studies will be conducted in accordance with the
principles of the Declaration of Helsinki and Good Clin-
ical Practice guidelines. Medical ethics approval has been
obtained by the medical ethics committee from the Aca-
demic Medical Centre in Amsterdam dated April 12th,
2012. Ethical approval has been obtained in the UK via the
National Research Ethics System (14/NE/1143; October
24th, 2014). Before randomisation, written informed con-
sent will be obtained from all patients.
Study outline
Participants will be recruited in the Inflammatory Bowel
Disease outpatient clinics of the participating medical
centres (Figure 1). Patients eligible for this study are ran-
domised to undergo laparoscopic appendectomy in day
care setting within six weeks of randomisation as op-
posed to no appendectomy. Surgery will be performed in
the including centre or one of the coordinating centres;
the Academic Medical Centre or University Hospitals
Birmingham.
At inclusion, patients will undergo endoscopic muco-
sal visualisation, either by an ileocolonoscopy or a
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test that needs to be < 100 ug/g, to confirm remission.
At the time of relapse or at the end of the 12 month
study period, patients will undergo a full colonoscopy to
assess mucosal appearance. The clinical and endoscopic
findings will be reported with the Mayo score. Using this
12-point scoring system, disease activity is evaluated
based on stool frequency, rectal bleeding, the physician’s
global assessment, and endoscopic appearance. In the
Mayo score, clinical remission is defined as a Total Mayo
score of 2 points or lower, with no individual subscore
exceeding 1 point. Mucosal healing is defined as an
absolute subscore for endoscopy of 0 or 1.
During the first 12 months of follow up, all patients
will receive oral maintenance therapy of 2 grams 5-
aminosalicylic acid (Salofalk®, Dr Falk Pharma GmbH,
Freiburg, Germany).
Outpatient clinic visits will be performed by the
gastroenterologist or research team at 6 weeks and 3, 6,
9 and 12 months after appendectomy or randomisation
in patients not undergoing appendectomy; other visits
are scheduled on indication. During these contacts the
non-invasive 9-point partial Mayo score will be assessed.
Patients will complete health related quality of life ques-
tionnaires (EQ-5D, EORTC-QLQ-C30-QL and IBDQ) at
inclusion and every 3 months thereafter for 12 months.
In the 5 years following the study the gastroenterologist
will be requested to measure the non-invasive 9-point
partial Mayo score every 6 months during outpatient
clinic appointments. Three years after randomisation a
further colonoscopy will be performed to assess long
term mucosal healing in the patients with longstanding
remission.
Laparoscopic appendectomy
Laparoscopic appendectomy is a relatively simple oper-
ation that can be done by most surgeons, in day care set-
ting or with a single night stay in hospital. The normal
reason to undertake an appendectomy is acute inflam-
mation of the appendix (appendicitis). There is a lifetime
incidence risk of 7% and patients diagnosed with this
condition almost all undergo appendectomy [19,20]. It is
in this forum that the laparoscopic (keyhole) method of
removing the appendix has become established over the
past 15 years and is now the recommended option
owing to its proven faster recovery times and fewer
wound complications [20].
The risks of removing a normal or non-inflamed appen-
dix in an elective setting are not known, as published data
exclusively refer to patients with confirmed or suspected
acute appendicitis undergoing emergency operations by
surgeons of variable seniority. It is reasonable to assume
that the risk of post-operative complications will be sig-
nificantly lower in our population than these publishedrates of 2.5-7.6% from patients with perforated appendi-
citis [20-22]. Specific complications that have been re-
ported include wound infection, intra-abdominal abscess,
iatrogenic bowel perforation, pneumonia and thrombosis.
The laparoscopic appendectomy in this study will be car-
ried out under general anaesthesia with the use of 3 tro-
cars or a Single Port system. Laparoscopic appendectomy
will be performed by a gastrointestinal or general surgeon
with sufficient experience in laparoscopic procedures (>20
procedures/year). When participating centres lack a quali-
fied surgeon the patient will be referred to the Academic
Medical Centre, University Hospitals Birmingham or a
surgeon that has enough experience in a collaborating
hospital nearby.
Statistical analysis
ACCURE Trial - Group size calculations are based on a
clinically relevant reduction in relapse rate from an
expected 40% in the control group to 20% in the inter-
vention group. With a 5% two-sided significance level,
82 patients per study arm will be needed to achieve an
80% power to detect such a difference using a Chi-
square test. Considering 10% patient drop out we expect
to have to include 184 patients in order to analyse 164
patients.
All data-analyses will be performed according to the
intention-to-treat principle.
The relapse rate, medication use and time to first re-
lapse of the two groups will be compared with Chi-square
testing, Mann Whitney U-testing and survival analysis.
Additional mixed-models repeated measures analysis of
variance will be used to investigate whether there is a dif-
ferent pattern of change over time between the two study
arms in the Mayo score and the EQ-5D, EORTC-QLQ-
C30-QL and IBDQ [23].
ACCURE-UK Trial - The target recruitment of this
randomised feasibility trial has been set at 48 patients as
it was felt this was the minimum number needed to sat-
isfy the objectives. By recruiting 48 patients, 24 will be
randomised to the intervention arm. This will provide
an estimation of operative morbidity rate and generalis-
able evidence about the length of stay, time off work and
impact upon HRQL. The full cohort (both arms) will
provide information on follow-up acceptability and attri-
tion rates. Running the trial at 6 centres across the UK
will generate a better understanding of likely patient
acceptance rates for the intervention and understand
potential barriers to recruitment in different settings.
Randomisation
In both studies, patient data are entered into a comput-
erized database and following the assignment of an
unchangeable computer generated number, patients will
be randomised to undergo laparoscopic appendectomy
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stratified by disease localization (rectum, left sided col-
itis, pancolitis), number of years diagnosed and number
of relapses in the past 12 months. Randomisation will
take place after all inclusion and exclusion criteria have
been verified and informed consent has been obtained.
Blinding
Blinding of patients and physicians during treatment is
unfeasible in this study. Endoscopic procedures will be
recorded with photo documentation. The endoscopic
follow- up for recurrence will be scored by independent
gastroenterologists blinded for the allocated treatment
strategy. Pathologists will be blinded to the treatment
allocation.
Data collection and monitoring
An electronic Case Report Form (eCRF) will include gen-
eral patient data: sex, age, medical history, disease char-
acteristics before and during the study period including
Mayo score, appendectomy parameters, complications,
mortality, duration of hospital stay and the patients’
responses to the questionnaires. Patients will be followed
for a period of 12 months. During this follow-up period
patients will complete sets of questionnaires (EQ-5D,
EORTC-QLQ-C30-QL and IBDQ). The questionnaires
can be filled in online. For this a personal email with the
invitation and access code will be sent to the patients by
mail. Patients not willing or unable to complete the
online questionnaires will receive identical paper ques-
tionnaires at their home address, accompanied by a free
return envelope.
Patients will be contacted by telephone every 3 months
by a study team member (i.e. trial nurse) to assess medi-
cation usage, complications, additional interventions, re-
admissions, duration of hospital stay and visits to the
outpatient clinic, number of days of sick leave and of
social in attendance and to ensure completions of the
questionnaires.Economic evaluation
ACCURE Trial - The economic evaluation of appendec-
tomy for established UC will be performed from a societal
perspective as a cost-effectiveness and cost-utility analysis
with a time horizon of 12 months. Primary outcomes in
these economic evaluations are the costs per patient with-
out relapse and costs per quality adjusted life-year (QALY)
respectively. Incremental cost-effectiveness ratios will be
calculated as the extra costs per additional patient without
relapse or per QALY gained. Furthermore, the cost-
effectiveness per prevented relapse will be calculated.
Additional sensitivity analyses will determine how chan-
ging treatment costs might impact the results.Direct medical costs and indirect non-medical costs
arising from losses in productivity will be assessed. Na-
tional unit costs will be used for the various health care
components, complemented by results from activity
based costing when needed. Both, the human capital ap-
proach as well as the friction cost method will be applied
to the indirect costs of sick leave from work.
The EQ-5D scoring profiles at successive measurements
during follow-up will be used to derive the corresponding
health utilities. This is done by applying computer algo-
rithms available from the literature. These algorithms
reflect preferences in the general population for various
health states and have been determined using time trade-
off elicitation techniques [24,25]. Having determined the
health utilities, a QALY estimate for each patient can be
calculated, accounting for the lengths of the periods in-
between successive measurements.
The ACCURE-UK trial does not contain any planned
health economic assessment as this does not form part
of the feasibility aims.Histopathological evaluation
Samples of appendicular tissues will be collected and
investigated at the Tytgat Laboratory of the Academic
Medical Centre Amsterdam according to a standard op-
erating procedure. Resected appendices will be analysed
by immunohistochemistry, FACS analysis and micro-
biota analysis will be performed. In the UK, translational
research samples will be centralised to the University of
Birmingham for analysis.Patient safety
An independent Data and Safety Monitoring Commit-
tee (DSMC) has been established to assure proper data
safety and relevance monitoring. The committee will
guard the safety of the included patients, give advice
on continuation of the study upon superiority of one
of the types of treatment, and will guard the methodo-
logical quality of the study. An interim review will be
performed at 25, 50 and 100 included patients. At
6 weeks after inclusion of these patients the trial’s
safety data will be evaluated. According to the Good
Clinical Practice guidelines, a list of Serious Adverse
events is defined. All events on this list have to be
reported by the local investigators to the trial coordi-
nators within 24 hours after the event. The DSMC will
be supplied with the number of (serious) adverse
events in both groups at the three mentioned time
points. If there is a skewed distribution of the number
of (serious) adverse events between the two groups an
efficacy analysis can be performed at the discretion of
the DSMC.
Gardenbroek et al. BMC Surgery  (2015) 15:30 Page 6 of 7Inclusion period
The ACCURE Trial (Netherlands) included the first pa-
tient in September 2012, the ACCURE-UK Trial com-
menced inclusion in December 2014. Full inclusion is
expected in August 2016.Discussion
Chronic relapsing diseases such as ulcerative colitis (UC)
incur a considerable long-term health burden to the
patients and health care systems. Early interventions that
reduce the rate of relapse and colectomy would offer
considerable benefit. Many patients with UC live with a
substantial symptom burden despite medical treatment;
three quarters report that symptoms affect their ability
to enjoy leisure activities and two thirds of patients feel
that symptoms affect their ability to perform at work
[26]. Therefore, it is imperative to explore novel treat-
ment options.
As early as 1987 the appendix was suggested to play a
role in ulcerative colitis, when an epidemiological study
found a lower appendectomy rate in UC patients com-
pared to healthy controls [27]. In the following years the
involvement of the appendix in UC was confirmed by
various other studies, suggesting the appendix’ role in
the immunologic cascade in the colonic mucosa of UC
patients [10,13-18,28]. The available literature suggests a
preferable clinical course in appendectomised patients
with UC, but strong evidence is lacking [11].
The primary outcome of interest in this research is
the proportion of patients with UC relapse, as defined
by the Mayo score. All patients in the study will be
treated with 2 grams 5-ASA maintenance therapy.
With this maintenance therapy, approximately 40% of
the patients with UC will have a disease relapse within
one year [7,29].
If an appendectomy can protect UC patients from
future use of expensive or potentially hazardous medica-
tion or even surgery, the initial additional costs and
potential side effects of appendectomy will be offset by
substantial gain in health and reduction in costs later on.
This is especially true for appendectomy, as this is a
relatively simple procedure that can be performed in day
care.
The ACCURE trial is a pragmatic multicentre trial
which is appropriately powered to detect any therapeutic
benefit from appendectomy in UC sufferers. If the
ACCURE-UK randomised feasibility trial shows that the
intervention appears to be acceptable to clinicians and
patients in the UK, and sufficient patients can be re-
cruited and followed-up, we anticipate undertaking fur-
ther parallel major multicentre phase III trial of the
intervention in the UK in the next year or two. Together,
these two trials will provide a powerful evidence base ofthe clinical efficacy of the intervention in a diverse
cohort.
Appendectomy is not currently employed as a thera-
peutic treatment for UC anywhere in the world. If our re-
search shows it to be safe, efficacious and cost-effective,
widespread uptake would be anticipated.
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